Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia

This study was supported by the Instituto de Salud Carlos III (ISCIII) PMP15/00007; Ministerio de Economía y Competitividad (MINECO) SAF2015-64885-R; Generalitat de Catalunya AGAUR 2014-SGR-795; and Gilead Spain (GLD15/00288). ECa is an Academia Researcher of the 'Institució Catalana de Recerca...

Descripción completa

Detalles Bibliográficos
Autores: Nadeu, Ferrán, Clot, G., Delgado, J., Suárez Puente, Xosé Antón|||0000-0001-9525-1483, López Otín, Carlos|||0000-0001-6964-1904
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Universidad de Oviedo (UNIOVI)
Repositorio:RUO. Repositorio Institucional de la Universidad de Oviedo
Idioma:inglés
OAI Identifier:oai:digibuo.uniovi.es:10651/44859
Acceso en línea:http://hdl.handle.net/10651/44859
https://dx.doi.org/10.1038/leu.2017.291
Access Level:acceso abierto
Descripción
Sumario:This study was supported by the Instituto de Salud Carlos III (ISCIII) PMP15/00007; Ministerio de Economía y Competitividad (MINECO) SAF2015-64885-R; Generalitat de Catalunya AGAUR 2014-SGR-795; and Gilead Spain (GLD15/00288). ECa is an Academia Researcher of the 'Institució Catalana de Recerca i Estudis Avançats' (ICREA) of the Generalitat de Catalunya. FN is supported by a pre-doctoral fellowship of the MINECO (BES-2016-076372). We are indebted to the Genomics core facility of the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). We are grateful to N Villahoz and MC Muro for their excellent work in the coordination of the CLL Spanish Consortium, and also thank C Capdevila, S Guijarro, L Pla and M Sánchez for their excellent technical assistance. We are also very grateful to all patients with CLL who have participated in this study.